About us Contacts Drug interactions: 390 212
Drug search by name

Fluvoxamine Extended-Release Capsules and Silenor

Determining the interaction of Fluvoxamine Extended-Release Capsules and Silenor and the possibility of their joint administration.

Check result:
Fluvoxamine Extended-Release Capsules <> Silenor
Relevance: 24.09.2023 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Ask your doctor before using doxepin together with fluvoxaMINE this can increase your blood levels of doxepin. This combination may cause side effects such as drowsiness, dry mouth, blurred vision, constipation, or urinating less than usual. Talk with your doctor before using these medications together. You may need a dose adjustment or special tests to safely take both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

GENERALLY AVOID: Coadministration with fluvoxamine may significantly increase the plasma concentrations of some tricyclic antidepressants (TCAs). The proposed mechanism is fluvoxamine inhibition of multiple hepatic microsomal enzymes involved in the metabolic clearance of TCAs. Mild to moderate increases in plasma levels have been reported for desipramine, while significant increases of several fold have been reported for clomipramine, imipramine, and trimipramine. Pharmacodynamically, the combination of fluvoxamine (or any other selective serotonin reuptake inhibitor) and a TCA may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5HT1A receptors.

MANAGEMENT: In general, the use of fluvoxamine (or other SSRIs) with TCAs should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Pharmacologic response and plasma TCA levels should be monitored more closely whenever fluvoxamine is added to or withdrawn from therapy in patients stabilized on their existing antidepressant regimen, and the TCA dosage adjusted as necessary. Patients should be monitored closely for signs and symptoms of TCA toxicity (e.g., sedation, dry mouth, blurred vision, constipation, urinary retention) and/or excessive serotonergic activity (e.g., CNS irritability, altered consciousness, confusion, myoclonus, ataxia, abdominal cramping, hyperpyrexia, shivering, pupillary dilation, diaphoresis, hypertension, and tachycardia).

References
  • Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE "The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes." Br J Clin Pharmacol 34 (1992): 262-5
  • Ereshefsky L, Riesemman C, Lam YW "Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6." Clin Pharmacokinet 29(Suppl 1) (1995): 10-8; discussion 18-9
  • Popli AP, Baldessarini RJ, Cole JO "Interactions of serotonin reuptake inhibitors with tricyclic antidepressants." Arch Gen Psychiatry 51 (1994): 666-7
  • Skjelbo E, Brosen K "Inhibitors of imipramine metabolism by human liver microsomes." Br J Clin Pharmacol 34 (1992): 256-61
  • Vandel S, Bertschy G, Baumann P, Bouquet S, Bonin B, Francois T, Sechter D, Bizouard P "Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients." Pharmacol Res 31 (1995): 347-53
  • Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13
  • Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2
  • Spina E, Pollicino AM, Avenoso A, Campo GM, Perucca E, Caputi AP "Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects." Ther Drug Monit 15 (1993): 243-6
  • Riesenman C "Antidepressant drug interactions and the cytochrome p450 system: a critical appraisal." Pharmacotherapy 15 (1995): s84-99
  • Taylor D "Selective serotonin reuptake inhibitors and tricyclic antidepressants in combination - interactions and therapeutic uses." Br J Psychiatry 167 (1995): 575-80
  • Spina E, Pollicino AM, Avenoso A, Campo GM, Caputi AP "Fluvoxamine-induced alterations in plasma concentrations of imipramine and desipramine in depressed patients." Int J Clin Pharmacol Res 13 (1993): 167-71
  • Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6
  • Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S "Fluvoxamine is a potent inhibitor of cytochrome P4501A2." Biochem Pharmacol 45 (1993): 1211-4
  • Spina E, Campo GM, Avenoso A, et al "Interaction between fluvoxamine and imipramine/desipramine in four patients." Ther Drug Monit 14 (1992): 194-6
  • Maskall DD, Lam RW "Increased plasma concentration of imipramine following augmentation with fluvoxamine." Am J Psychiatry 150 (1993): 1566
  • "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.
  • Vonmoltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI "Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants." J Clin Psychopharmacol 15 (1995): 125-31
  • Seifritz E, Holsboertrachsler E, Hemmeter U, Eap CB, Baumann P "Increased trimipramine plasma levels during fluvoxamine comedication." Eur Neuropsychopharmacol 4 (1994): 15-20
  • Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763
  • Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2
  • Bertschy G, Vandel S, Vandel B, Allers G, Volmat R "Fluvoxamine-tricyclic antidepressant interaction. An accidental finding." Eur J Clin Pharmacol 40 (1991): 119-20
Fluvoxamine Extended-Release Capsules

Generic Name: fluvoxamine

Brand name: Luvox, Luvox CR

Synonyms: Fluvoxamine

Silenor

Generic Name: doxepin

Brand name: Silenor, Sinequan, Sinequan

Synonyms: n.a.

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle